GM-2505 clinical trials

A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD

This study is testing a new medicine, GM-2505, for moderate to severe depression. It's looking at how safe it is and if it helps people feel better. We're inviting adults aged 18-65 with depression to take part.